Borges Margarida, Sampaio Filipa, Costa João, Freitas Paula, Matias Dias Carlos, Gaio Vânia, Conde Vasco, Figueira Débora, Pinheiro Bernardete, Silva Miguel Luís
IQVIA, Lisbon, Portugal.
Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Obes Facts. 2025;18(2):107-120. doi: 10.1159/000541781. Epub 2024 Nov 5.
The prevalence of overweight and obesity has increased in the last decades, posing significant health and economic impacts globally. These conditions are related to several non-communicable diseases, including cardiovascular disease, type II diabetes, and cancer. This study estimated the disease burden and healthcare costs associated with overweight and obesity in the adult population in mainland Portugal, in 2018.
Burden of disease was measured in disability-adjusted life years (DALYs) following Global Burden of Disease (GBD) methodology. DALYs were calculated as the sum of years of life lost (YLL) and years lived with disability (YLD). The analyses included morbidity, mortality, and related costs directly related to overweight and obesity, as well as the attributable morbidity, mortality, and related costs of 25 selected diseases related to obesity (DrO). A prevalence-based cost analysis was conducted a from the perspective of the public National Health Service, including costs related to inpatient, outpatient care, and pharmacological treatment.
In 2018, total DALY amounted to 260,943, with 75% due to premature death (196,438 YLL) and 25% due to disability (64,505 YLD). The economic burden of overweight and obesity was estimated at approximately EUR 1,148 million. Of these, approximately EUR 13.3 million (1%) were costs related to the treatment of obesity, and the remaining were costs of DrO attributed to overweight and obesity. Outpatient care corresponded to 43% of total costs, pharmacological treatment 38%, and inpatient care 19%. Cardiovascular and cerebrovascular diseases were the largest contributor to total costs (38%), followed by type II diabetes (34%).
Overweight and obesity incur a large disease and economic burden to the public healthcare sector, representing approximately 0.6% of the country's gross domestic product and 5.8% of public health expenditures.
在过去几十年中，超重和肥胖的患病率有所上升，在全球范围内造成了重大的健康和经济影响。这些情况与多种非传染性疾病有关，包括心血管疾病、II型糖尿病和癌症。本研究估计了2018年葡萄牙大陆成年人口中超重和肥胖相关的疾病负担和医疗费用。
按照全球疾病负担（GBD）方法，以伤残调整生命年（DALYs）衡量疾病负担。DALYs计算为生命损失年数（YLL）和残疾生存年数（YLD）之和。分析包括与超重和肥胖直接相关的发病率、死亡率及相关费用，以及25种选定的肥胖相关疾病（DrO）的归因发病率、死亡率及相关费用。从国家公共卫生服务的角度进行了基于患病率的成本分析，包括住院、门诊护理和药物治疗的费用。
2018年，DALYs总数达260,943，其中75%归因于过早死亡（196,438 YLL），25%归因于残疾（64,505 YLD）。超重和肥胖的经济负担估计约为1.148亿欧元。其中，约1330万欧元（1%）为肥胖治疗费用，其余为归因于超重和肥胖的DrO费用。门诊护理占总费用的43%，药物治疗占38%，住院护理占19%。心血管和脑血管疾病是总费用的最大贡献者（38%），其次是II型糖尿病（34%）。
超重和肥胖给公共医疗部门带来了巨大的疾病和经济负担，约占该国国内生产总值的0.6%和公共卫生支出的5.8%。
